After Sanofi lost the bidding war for Horizon Therapeutics in December, the question wasn’t so much if the French pharma would pursue another buyout, but when. Now, rather than making another go at rare diseases, Sanofi is doubling down on one of its long-held areas of expertise: diabetes.
